Skip to main content
. 2020 Aug 12;111(10):3714–3725. doi: 10.1111/cas.14580

FIGURE 3.

FIGURE 3

Kaplan‐Meier estimates of the rates of overall survival (OS), excluding CML‐unrelated death, relative to the CCI score. OS, excluding CML‐unrelated death, in the entire cohort (A), the imatinib cohort (B), and the 2GTKI cohort (C). 2GTKI, second‐generation tyrosine kinase inhibitor; CCI, Charlson Comorbidity Index